drug development

A unique collection of 101 compounds with defined hematopoietic toxicity for high throughput and high content drug screening;

A unique collection of 701 preclinical compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2960 approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1440 hepatotoxicity causing compounds, a powerful tool for drug toxicity study, can be used for HTS and HCS screening;

A unique collection of 4080 compounds for high-throughput screening and high-content screening,

3400 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2400 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of 653 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 540 gut microbial metabolites which can be used for HTS and HCS;

A unique collection of 3550 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);

A collection of 18720 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

A unique collection of 1855 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3163 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 4655 pure natural products and their derivatives with known biological activity for drug discovery, pharmacological study, stem cell differentiation, fingerprint study and quality research, and can be used for high throughput screen

A unique collection of 4221 natural products for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 500 natural alkaloids can be used for high throughput and high content screening;

A unique collection of 1812 natural products with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3011 compounds (TCM monomers) sourcing from traditional Chinese Medicines, is a powerful tool for drug discovery and research in mechanism;

A unique collection of 5120 approved and clinical drugs for high throughput screening (HTS) and high content screening (HCS);

891 peptides can be used in peptide drug development and signaling transduction and mechanism study;

A unique collection of 680 EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 142 microtubule-targeted compounds can be used in HTS and HCS;

A unique collection of 631 nuclear receptor signaling targeted compounds for high throughput and high content screening;